Clinical Trial Information Request for Protocol 25-807 Title The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone